Literature DB >> 33067687

Morbidity and Mortality of Large-Vessel Vasculitides.

Matthew J Koster1, Kenneth J Warrington2, Eric L Matteson2.   

Abstract

PURPOSE OF REVIEW: Giant cell arteritis (GCA) and Takayasu arteritis (TAK) comprise the primary systemic large-vessel vasculitides. In these conditions, arterial stenosis, occlusion, aneurysm, and dissection can lead to severe disease-related consequences. This review focuses on disease-related manifestations of GCA and TAK, emphasizing the impact of these findings on long-term morbidity and mortality. RECENT
FINDINGS: Vision loss remains a main contributor of morbidity in GCA. Non-invasive imaging allows for recognition of aortic disease in GCA but monitoring and intervention guidelines require further development. TAK represents a severe disease of early-onset with high risk of morbidity due to aortic, pulmonary, cardiovascular, and neurologic involvement. Overall, patients with GCA have similar mortality rates to comparators but mortality is notably higher than the general population in TAK. A multidisciplinary approach of expert subspecialists is required to assist with the complex care of patients with GCA and TAK in order to appropriately surveil, identify, and address the multi-faceted co-morbidities of these diseases.

Entities:  

Keywords:  Giant cell arteritis; Large-vessel vasculitis; Morbidity; Mortality; Outcome; Takayasu arteritis

Year:  2020        PMID: 33067687     DOI: 10.1007/s11926-020-00963-y

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  2 in total

Review 1.  The role of neutrophils in rheumatic disease-associated vascular inflammation.

Authors:  Lihui Wang; Raashid Luqmani; Irina A Udalova
Journal:  Nat Rev Rheumatol       Date:  2022-01-17       Impact factor: 20.543

Review 2.  Large-vessel vasculitis.

Authors:  Dan Pugh; Maira Karabayas; Neil Basu; Maria C Cid; Ruchika Goel; Carl S Goodyear; Peter C Grayson; Stephen P McAdoo; Justin C Mason; Catherine Owen; Cornelia M Weyand; Taryn Youngstein; Neeraj Dhaun
Journal:  Nat Rev Dis Primers       Date:  2022-01-06       Impact factor: 65.038

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.